Paradigm Shift in Patient Treatment

• The paradigm of patient treatment is changing from the ‘Conventional Method’ (One treatment fits all) to ‘Precision Medicine’ (Personalized Diagnostics) based on the characteristics and information of each patient
• The global personalized medicine market is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2020 to 2030

TDRA (Tumorid drug response assay)

• We developed a TDRA analysis method that is a next-generation anti-cancer drug response assay based on patient-derived tumoroids

• Plan to clinical trials (200-300 patients by each cancer type) in the second half of 2022 for patients of lung, colorectal, and ovarian cancer (Participating organizations: Asan Medical Center & Samsung Medical Center)
• Based on results of clinical trials, TDRA, a personalized drug screening system using tumoroids, would be developed as a standard method of analysis